{
    "organizations": [],
    "uuid": "4c2eb34106a1926858e5c95ac91aed242f4b3a58",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-biogen-reports-top-line-results-fr/brief-biogen-reports-top-line-results-from-phase-2b-study-of-natalizumab-idUSASM000J1H",
    "ord_in_thread": 0,
    "title": "BRIEF-Biogen Reports Top-Line Results From Phase 2B Study Of Natalizumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 7 (Reuters) - Biogen Inc:\n* BIOGEN REPORTS TOP-LINE RESULTS FROM PHASE 2B STUDY OF NATALIZUMAB IN ACUTE ISCHEMIC STROKE\n* BIOGEN INC - PRIMARY AND SECONDARY EFFICACY ENDPOINTS WERE NOT MET IN ACTION 2 STUDY\n* BIOGEN INC - FURTHER DEVELOPMENT OF NATALIZUMAB IN ACUTE ISCHEMIC STROKE WILL NOT BE PURSUED\n* BIOGEN INC - IN MIDDLE OF 2018, BIOGEN PLANS TO INITIATE A GLOBAL PHASE 3 STUDY OF BIIB093 IN INDIVIDUALS WITH LARGE HEMISPHERIC INFARCTION\n* BIOGEN INC - IN STUDY, SECONDARY AND EXPLORATORY ENDPOINTS SUGGESTED NATALIZUMAB TREATMENT IMPROVED CLINICAL OUTCOMES COMPARED WITH PLACEBO Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-07T20:36:00.000+02:00",
    "crawled": "2018-02-09T05:48:05.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "biogen",
        "inc",
        "biogen",
        "report",
        "result",
        "phase",
        "2b",
        "study",
        "natalizumab",
        "acute",
        "ischemic",
        "stroke",
        "biogen",
        "inc",
        "primary",
        "secondary",
        "efficacy",
        "endpoint",
        "met",
        "action",
        "study",
        "biogen",
        "inc",
        "development",
        "natalizumab",
        "acute",
        "ischemic",
        "stroke",
        "pursued",
        "biogen",
        "inc",
        "middle",
        "biogen",
        "plan",
        "initiate",
        "global",
        "phase",
        "study",
        "biib093",
        "individual",
        "large",
        "hemispheric",
        "infarction",
        "biogen",
        "inc",
        "study",
        "secondary",
        "exploratory",
        "endpoint",
        "suggested",
        "natalizumab",
        "treatment",
        "improved",
        "clinical",
        "outcome",
        "compared",
        "placebo",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}